Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:227,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:203,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Chou WilliamOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:575,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Cale Edgar B.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:203,000Price:--
-
Feb 13, 2024 (filed on Feb 13, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,470Price:$0.97
-
Feb 13, 2024 (filed on Feb 13, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,638Price:$0.97
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,000Price:--
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,000Price:--
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,000Price:--
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,000Price:--
Filings by filing date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:227,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:203,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Chou WilliamOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:575,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Cale Edgar B.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:203,000Price:--
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,000Price:--
-
Feb 13, 2024 (filed on Feb 13, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,470Price:$0.97
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Borthwick KathleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,000Price:--
-
Feb 10, 2024 (filed on Feb 13, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,000Price:--
-
Feb 10, 2022 (filed on Feb 13, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
-
Feb 10, 2022 (filed on Feb 13, 2024)Insider Name:Forman Mark SOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Commerce Square 2005 Market Street, 39Th Floor PHILADELPHIA PA 19103 |
Tel: | N/A |
Website: | https://www.passagebio.com |
IR: | See website |
Key People | ||
William Chou President, Chief Executive Officer, Director | Kathleen Borthwick Chief Financial Officer | Edgar B. Cale General Counsel, Company Secretary | Mark Forman Chief Medical Officer |
Business Overview |
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer's disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease. |
Financial Overview |
For the fiscal year ended 31 December 2023, Passage Bio Inc revenues was not reported. Net loss decreased 25% to $102.1M. Lower net loss reflects Research and development decrease of 28% to $55.9M (expense), Stock-based Compensation in SGA decrease of 50% to $5.4M (expense), Interest Income increase from $2.3M to $5.6M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.50 to -$1.86. |
Employees: | 58 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$99.19M as of Dec 31, 2023 |
Net annual income (TTM): | -$102.06M as of Dec 31, 2023 |
Free cash flow (TTM): | -$78.41M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 61,611,796 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |